QBIO - Q BioMed's chemo-therapy an Orphan Drug in the U.S. for liver cancer

The FDA has designated Orphan Drug status to Q BioMed's (QBIO) Uttroside-B, a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma, the most common form of liver cancer.In preclinical studies, Uttroside-B was up to 10-times more potent against hepatocellular carcinoma cells than Sorafinib, the standard of care drug at the time. Investigational New Drug application submission is expected this year.As an Orphan Drug, Uttroside-B may benefit from a seven-year market exclusively following marketing approval, grant funding for clinical trials.

For further details see:

Q BioMed's chemo-therapy an Orphan Drug in the U.S. for liver cancer